New applications of cancer immunotherapy

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 7, 2002, Pages 1-4

  Agarwala, Sanjiv S ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; DACARBAZINE; HISTAMINE; INTERLEUKIN 2; REACTIVE OXYGEN METABOLITE; TAMOXIFEN; TEMOZOLOMIDE; VINBLASTINE;

CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HYPOTENSION; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; UNITED STATES;

EID: 0036274145     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.33082     Document Type: Article

References (47)

1. The rate of malignant melanoma in the United States: Are we making an impact?
2. Prognostic factors in 1,521 melanoma patients with distant metastases
3. A new American Committee on cancer staging system for cutaneous melanoma
4. Treatment of uveal melanoma metastatic to the liver: A review of the M. D. Anderson Cancer Center experience and prognostic factors
5. Ananalysis of prognostic factors in 4000 patients with cutaneous melanoma
6. Clinical drug development: Ananalysis of phase II trials, 1970-1985
7. Cutaneous melanoma
8. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma
9. Combination chemotherapy with cisplatin, carmustine, dacarbazine, tamoxifen in metastatic melanoma
10. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma
11. The importance of tamoxifen to cisplatin containing regimen in the treatment of metastatic melanoma
12. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma
13. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma
14. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma
15. Cisplatin (C), vinblastine (V), and dacarbazine (D) (CVD) versus dacarbazine alone in metastatic melanoma: Preliminary results of a phase III Cancer Community Oncology Program (CCOP) trial
16. Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2, two patients with metastatic cancer
17. Therapeutic use of interleukin-2 and lymphokine activated killer (LAK) cells
18. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2
19. A phase II study of interleukin-2 and lymphokine activated killer (LAK) cells in patients with metastatic malignant melanoma
20. Interleukin-2 therapy in patients with metastatic malignant melanoma: A phase II study
21. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update
22. Interferons in the treatment of malignant melanoma. A review of recent trials
23. Newer immunologic approaches to the treatment of patients with melanoma
24. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with IL-2 and IFN-alpha-2b
25. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group
26. Dacarbazine, cisplatin, and IFN-α with or without IL-2 in advanced melanoma (EORTC trial 18951)
27. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial
28. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alfa-2b in advanced melanoma outpatients: Results from an Italian multicenter phase III randomized clinical trial
29. Biology of natural killer cells
30. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor specific T cell- and natural killer cell-mediated cytotoxicity
31. Monocytes and other infiltrating cells in human colorectal rumors identified by monoclonal antibodies
32. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma
33. Infiltration of primary and metastatic melanomas with macrophages of the 25F9-positive phenotype
34. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression
35. Induction of apoptosis in natural killer cells by monocyte-derived reactive oxygen metabolites
36. Histaminergic regulation of antibody-dependent cellular cytotoxicity of granulocytes, monocytes and natural killer cells
37. Histaminergic regulation of NK-cells: Protection against monocyte-induced apoptosis
38. Histaminergic regulation of NK-cells: Role of monocyte-derived, reactive oxygen metabolites
39. Histamine protects T cells and natural killer cells against oxidative stress
40. Synergistic NK cell activation by histamine and interleukin-2
41. Regulation of the NK-cell response to IFN-α by biogenic amines
42. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukemia
43. NK cell-mediated killing of AML blasts: Role of histamine, monocytes and reactive oxygen metabolites
44. Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignancies
45. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma
46. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma